Evidence map›Paper›PMID 40545739›Full record

ArticleBiomarkers in medicine2025

Diagnosis and monitoring of breast cancer with a novel circulating tumor cells enrichment device.

Zhiyun Gong, Jing Yan, Yi Zhang, Yan Chen, Aoshuang Li, Xiaorong Yang, Weizhong Shi, Lin Guo, Tiantian Dai, Feng Dong and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhiyun GongDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Jing YanHolosensor Medical Technology Ltd, Suzhou, China.
Yi ZhangDepartment of clinical laboratory, Shanghai International Medical Center, Shanghai, China.
Yan ChenDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Aoshuang LiDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiaorong YangDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Weizhong ShiDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Lin GuoDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Tiantian DaiDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Feng DongDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Renquan LuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsCirculating tumor cells (CTCs) are a critical biomarker for cancer evaluation. The more excellent detection system for CTCs is in demand. PATIENTS &

methodsOne hundred and thirty-seven breast cancer patients, 97 patients with benign breast diseases, and 42 healthy volunteers were enrolled. Four milliliters of peripheral blood was used for CTCs detection. The performance was assessed by the receiver operator characteristic curve. A short-term follow-up with 23 patients was presented for real-time monitoring.

resultsIn clinical, CTCs were found in 96.35% of patients with malignant breast cancer and 25.77% of patients with benign breast diseases but not in healthy group, by CytoBot® 2000. The sensitivity and specificity of 89.8% and 98.6%, respectively, when the cutoff value of 1.5 CTCs per 4 ml whole blood. Significant differences of CTC count were found between malignant and nonmalignant group (

conclusionCTCs and this platform both have practical implications in clinical breast cancer diagnosis and monitoring.

Indexed as

Breast NeoplasmsCell SeparationNeoplastic Cells, CirculatingAdultAgedBiomarkers, TumorCase-Control StudiesFemaleHumansLeukocyte Common AntigensMiddle AgedROC CurveBiomarkers, TumorLeukocyte Common AntigensBreast cancercancer diagnosis and monitoringcirculating tumor cellsDual-positive CTCtumour progression

Identifiers

PMID40545739
PMCPMC12233826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.